NTLA DEADLINE TODAY: ROSEN, RECOGNIZED INVESTOR COUNSEL, Encourages Intellia Therapeutics, Inc. Investors to Secure Counsel Before Important April 14 Deadline in Securities Class Action - NTLA Apr 14, 2025 01:23PM
NTLA DEADLINE TOMORROW: ROSEN, TOP RANKED GLOBAL COUNSEL, Encourages Intellia Therapeutics, Inc. Investors to Secure Counsel Before Important April 14 Deadline in Securities Class Action - NTLA Apr 13, 2025 01:18PM
NTLA DEADLINE MONDAY: ROSEN, A LEADING LAW FIRM, Encourages Intellia Therapeutics, Inc. Investors with Losses in Excess of $50K to Secure Counsel Before Important April 14 Deadline in Securities Class Apr 11, 2025 05:28PM
NTLA DEADLINE: ROSEN, TOP RANKED INVESTOR COUNSEL, Encourages Intellia Therapeutics, Inc. Investors to Secure Counsel Before Important April 14 Deadline in Securities Class Action - NTLA Apr 10, 2025 05:23PM
NTLA DEADLINE: ROSEN, A TRUSTED AND LEADING LAW FIRM, Encourages Intellia Therapeutics, Inc. Investors to Secure Counsel Before Important April 14 Deadline in Securities Class Action - NTLA Apr 9, 2025 05:18PM
View Older Stories

Apr 7, 2025 01:07PM NTLA IMPORTANT DEADLINE: ROSEN, A LEADING LAW FIRM, Encourages Intellia Therapeutics, Inc. Investors to Secure Counsel Before Important April 14 Deadline in Securities Class Action - NTLA
Apr 6, 2025 01:02PM NTLA IMPORTANT DEADLINE: ROSEN, GLOBAL INVESTOR COUNSEL, Encourages Intellia Therapeutics, Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important April 14 Deadline in Securit
Apr 5, 2025 12:48PM NTLA DEADLINE ALERT: ROSEN, NATIONAL TRIAL COUNSEL, Encourages Intellia Therapeutics, Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important April 14 Deadline in Securities C
Apr 4, 2025 12:39PM NTLA DEADLINE ALERT: ROSEN, SKILLED INVESTOR COUNSEL, Encourages Intellia Therapeutics, Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important April 14 Deadline in Securities
Apr 2, 2025 03:47PM NTLA DEADLINE ALERT: ROSEN, TOP-RANKED INVESTOR COUNSEL, Encourages Intellia Therapeutics, Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important April 14 Deadline in Securit
Mar 31, 2025 01:59PM ROSEN, RECOGNIZED INVESTOR COUNSEL, Encourages Intellia Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - NTLA
Mar 30, 2025 11:15AM ROSEN, SKILLED INVESTOR COUNSEL, Encourages Intellia Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - NTLA
Mar 28, 2025 02:36PM ROSEN, A LEADING LAW FIRM, Encourages Intellia Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - NTLA
Mar 27, 2025 02:01PM ROSEN, A LEADING INVESTOR RIGHTS LAW FIRM, Encourages Intellia Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - NTLA
Mar 26, 2025 01:56PM ROSEN, A TOP RANKED LAW FIRM, Encourages Intellia Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - NTLA
Mar 25, 2025 01:51PM ROSEN, GLOBAL INVESTOR COUNSEL, Encourages Intellia Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - NTLA
Mar 22, 2025 05:17PM ROSEN, A LEADING INVESTOR RIGHTS LAW FIRM, Encourages Intellia Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - NTLA
Mar 21, 2025 05:12PM ROSEN, A LEADING LAW FIRM, Encourages Intellia Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - NTLA
Mar 20, 2025 05:07PM ROSEN, A HIGHLY RECOGNIZED LAW FIRM, Encourages Intellia Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - NTLA
Mar 17, 2025 06:36PM TOP RANKED ROSEN LAW FIRM Encourages Intellia Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - NTLA
Mar 15, 2025 08:30AM ROSEN, A LONGSTANDING LAW FIRM, Encourages Intellia Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - NTLA
Mar 11, 2025 06:19PM ROSEN, GLOBAL INVESTOR COUNSEL, Encourages Intellia Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - NTLA
Mar 10, 2025 06:01PM ROSEN, GLOBAL INVESTOR COUNSEL, Encourages Intellia Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - NTLA
Mar 7, 2025 10:52PM ROSEN, A TOP-RANKED LAW FIRM, Encourages Intellia Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - NTLA
Mar 6, 2025 04:45PM ROSEN, SKILLED INVESTOR COUNSEL, Encourages Intellia Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - NTLA
Mar 4, 2025 08:06PM ROSEN, NATIONAL INVESTOR COUNSEL, Encourages Intellia Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - NTLA
Mar 3, 2025 08:01PM ROSEN, HIGHLY RECOGNIZED INVESTOR RIGHTS COUNSEL, Encourages Intellia Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - NTLA
Mar 2, 2025 02:15PM ROSEN, TOP RANKED INVESTOR COUNSEL, Encourages Intellia Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - NTLA
Mar 1, 2025 02:15PM ROSEN, A LEADING LAW FIRM, Encourages Intellia Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - NTLA
Feb 28, 2025 01:08PM ROSEN, GLOBAL INVESTOR COUNSEL, Encourages Intellia Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - NTLA
Feb 26, 2025 06:15PM ROSEN, A GLOBALLY RESPECTED LAW FIRM, Encourages Intellia Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - NTLA
Feb 25, 2025 06:10PM ROSEN, GLOBAL INVESTOR COUNSEL, Encourages Intellia Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - NTLA
Feb 23, 2025 10:27PM ROSEN, A RANKED AND LEADING LAW FIRM, Encourages Intellia Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - NTLA
Feb 22, 2025 10:23PM ROSEN, HIGHLY RECOGNIZED INVESTOR COUNSEL, Encourages Intellia Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - NTLA
Feb 20, 2025 05:11PM ROSEN, A LEADING INVESTOR RIGHTS LAW FIRM, Encourages Intellia Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - NTLA
Feb 17, 2025 03:42PM ROSEN, TOP-RANKED INVESTOR COUNSEL, Encourages Intellia Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - NTLA
Jun 3, 2024 05:51AM Intellia Therapeutics (NTLA) Reports Positive Long-Term Data from Phase 1 Study of NTLA-2002
Jun 2, 2024 08:00AM Intellia Therapeutics Announces Positive Long-Term Data from Ongoing Phase 1 Study of NTLA-2002, an Investigational In Vivo CRISPR Gene Editing Treatment for Hereditary Angioedema (HAE)
Jan 24, 2024 07:00AM SparingVision Reaches Final Dose Escalation Step in PRODYGY Trial with SPVN06 for retinitis pigmentosa
Nov 14, 2023 07:31AM Intellia Therapeutics (NTLA) Receives EU Orphan Drug Designation for NTLA-2002
Nov 14, 2023 07:30AM Intellia Therapeutics Receives European Union Orphan Drug Designation for NTLA-2002, an Investigational In Vivo CRISPR Genome Editing Treatment for Hereditary Angioedema
Nov 9, 2023 07:30AM Intellia Therapeutics Announces Third Quarter 2023 Financial Results and Highlights Recent Company Progress
Nov 2, 2023 07:03AM Intellia Therapeutics (NTLA) Presents New Interim Data from the Ongoing Phase 1 Study of NTLA-2001
Nov 2, 2023 07:00AM Intellia Presents New Interim Data from the Ongoing Phase 1 Study of NTLA-2001 at the 4th International ATTR Amyloidosis Meeting
Oct 26, 2023 07:30AM Intellia Therapeutics to Present Updated Data from Ongoing Phase 1 Study of NTLA-2001 for the Treatment of Transthyretin (ATTR) Amyloidosis and Hold Conference Call to Discuss Third Quarter 2023 Earni
Oct 18, 2023 07:02AM Intellia Therapeutics (NTLA) Receives FDA Clearance of IND to Initiate a Phase 3 Trial of NTLA-2001
Oct 18, 2023 07:00AM Intellia Therapeutics Announces FDA Clearance of Investigational New Drug (IND) Application to Initiate a Pivotal Phase 3 Trial of NTLA-2001 for the Treatment of Transthyretin (ATTR) Amyloidosis with
Oct 13, 2023 08:40AM Intellia Therapeutics (NTLA) Receives PRIME Designation From EMA for NTLA-2002, an Investigational In Vivo CRISPR Genome Editing Treatment for Hereditary Angioedema
Oct 13, 2023 08:38AM Intellia Therapeutics Receives Priority Medicines (PRIME) Designation From the European Medicines Agency for NTLA-2002, an Investigational In Vivo CRISPR Genome Editing Treatment for Hereditary Angioe
Oct 3, 2023 07:02AM Regeneron (REGN) and Intellia (NTLA) Announce Expanded Research Collaboration to Develop CRISPR-Based Therapies for the Treatment of Neurological and Muscular Diseases
Oct 3, 2023 07:00AM Regeneron and Intellia Announce Expanded Research Collaboration to Develop CRISPR-Based Therapies for the Treatment of Neurological and Muscular Diseases
Aug 30, 2023 07:00AM SparingVision Reports Positive Initial Safety Data from the first cohort treated in its PRODYGY Phase I/II Gene Therapy Trial
Aug 3, 2023 07:30AM Intellia Therapeutics Announces Second Quarter 2023 Financial Results and Highlights Recent Company Progress
Jul 27, 2023 07:30AM Intellia Therapeutics to Hold Conference Call to Discuss Second Quarter 2023 Earnings and Company Updates
Jun 12, 2023 05:24AM Intellia Therapeutics (NTLA) Announces New Positive Clinical Data from Phase 1 Study of NTLA-2002
View Older Stories